ES2182915T3 - Procedimiento de purificacion del factor viii - Google Patents

Procedimiento de purificacion del factor viii

Info

Publication number
ES2182915T3
ES2182915T3 ES95937285T ES95937285T ES2182915T3 ES 2182915 T3 ES2182915 T3 ES 2182915T3 ES 95937285 T ES95937285 T ES 95937285T ES 95937285 T ES95937285 T ES 95937285T ES 2182915 T3 ES2182915 T3 ES 2182915T3
Authority
ES
Spain
Prior art keywords
viii
factor viii
gel
procedure
invention refers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95937285T
Other languages
English (en)
Inventor
Anna-Lisa Smeds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Application granted granted Critical
Publication of ES2182915T3 publication Critical patent/ES2182915T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN PROCEDIMIENTO PARA PURIFICAR EL FACTOR VIII RECOMBINANTE DE COAGULACION MEDIANTE LA CARGA DE UNA SOLUCION ACUOSA QUE CONTIENE FACTOR VIII EN UN GEL DE CROMATOGRAFIA DE INTERACCION HIDROFOBA (HIC), EN DONDE AL MENOS HAY PRESENTE UN SURFACTANTE EN LA SOLUCION ACUOSA Y/O UNA SOLUCION DE TAMPON ES UTILIZADA PARA EQUILIBRAR EL GEL ANTES DE CARGAR LA SOLUCION ACUOSA EN EL GEL. LA PRESENCIA DE UN SURFACTANTE AL CARGAR LA SOLUCION QUE CONTIENE FACTOR VIII EN EL GEL HIC, HACE POSIBLE SEPARAR EFICAZMENTE LAS MOLECULAS DE FACTOR VIII INTACTAS Y ACTIVAS DE MOLECULAS CON DESVIOS ESTRUCTURALES. CON LA PRESENTE INVENCION ES ADEMAS POSIBLE REDUCIR EL CONTENIDO DE ADN Y/O CONTAMINANTES DE CELULA CHO DE FORMA CONSIDERABLE Y AUMENTAR LA ACTIVIDAD DEL PRODUCTO DE FACTOR VIII A UNA EXTENSION HASTA AHORA DESCONOCIDA. LA INVENCION SE REFIERE ADEMAS A UNA SOLUCION ACUOSA QUE CONTIENE FACTOR VIII RECOMBINANTE QUE HA SIDO PURIFICADO DE ACUERDO CON EL PRESENTE PROCEDIMIENTO Y ALUSO DE DICHA SOLUCION ACUOSA, PARA LA FABRICACION DE UN MEDICAMENTO PARA ADMINISTRACION A UN PACIENTE QUE TENGA LOS SINTOMAS DE HEMOFILIA. ADEMAS, LA INVENCION SE REFIERE A UN METODO DE TRATAMIENTO DE HEMOFILIA MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE FACTOR VIII RECOMBINANTE QUE HA SIDO PURIFICADO DE ACUERDO CON EL PRESENTE PROCEDIMIENTO.
ES95937285T 1994-11-14 1995-11-14 Procedimiento de purificacion del factor viii Expired - Lifetime ES2182915T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9403914A SE503424C2 (sv) 1994-11-14 1994-11-14 Process för rening av rekombinant koagulationsfaktor VIII

Publications (1)

Publication Number Publication Date
ES2182915T3 true ES2182915T3 (es) 2003-03-16

Family

ID=20395963

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95937285T Expired - Lifetime ES2182915T3 (es) 1994-11-14 1995-11-14 Procedimiento de purificacion del factor viii

Country Status (13)

Country Link
US (1) US6005082A (es)
EP (1) EP0792281B1 (es)
JP (1) JP3871710B2 (es)
AT (1) ATE225368T1 (es)
AU (1) AU691993B2 (es)
CA (1) CA2202873C (es)
DE (1) DE69528471T2 (es)
DK (1) DK0792281T3 (es)
ES (1) ES2182915T3 (es)
NZ (1) NZ295810A (es)
PT (1) PT792281E (es)
SE (1) SE503424C2 (es)
WO (1) WO1996015140A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1820516B1 (en) 1999-02-22 2013-07-24 University of Connecticut Novel albumin-free factor VIII formulations
US6822081B2 (en) * 2000-01-13 2004-11-23 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Process for the isolation and/or purification of a proteinaceous material
EP1681299B1 (en) 2000-03-27 2009-11-11 Genetics Institute, LLC Methods for purifying highly anionic proteins
EP1404428B1 (en) * 2001-06-05 2006-07-19 Genetics Institute, LLC Methods for purifying highly anionic proteins
US7427659B2 (en) * 2003-10-24 2008-09-23 Amgen Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
BRPI0814220B8 (pt) * 2007-07-11 2021-05-25 Novo Nordisk As purificação de fator viii usando uma resina multimodal ou de modo misto
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
KR20130020789A (ko) 2010-05-19 2013-02-28 에프. 호프만-라 로슈 아게 소수성 상호작용 크로마토그래피 방법
EP2652491B1 (en) 2010-12-15 2017-11-29 Baxalta GmbH Eluate collection using conductivity gradient
BRPI1105317A2 (pt) 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
EP3642225A1 (en) * 2017-06-23 2020-04-29 Baxalta Incorporated Purification of factor viii subspecies
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
FR2662166A1 (fr) * 1990-05-18 1991-11-22 Fondation Nale Transfusion San Procede de preparation de facteur viii de tres haute purete comprenant une etape rapide d'immunoadsorption.
GB9211538D0 (en) * 1992-06-01 1992-07-15 Blake David R Antiinflammatory agent
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
EP0674531A1 (de) * 1992-12-16 1995-10-04 IMMUNO Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates

Also Published As

Publication number Publication date
JP3871710B2 (ja) 2007-01-24
PT792281E (pt) 2003-02-28
EP0792281B1 (en) 2002-10-02
NZ295810A (en) 1998-08-26
AU691993B2 (en) 1998-05-28
EP0792281A1 (en) 1997-09-03
MX9703470A (es) 1997-07-31
DK0792281T3 (da) 2003-02-03
CA2202873A1 (en) 1996-05-23
SE9403914L (sv) 1996-05-15
CA2202873C (en) 2011-06-21
JPH10508841A (ja) 1998-09-02
ATE225368T1 (de) 2002-10-15
DE69528471D1 (de) 2002-11-07
AU3943895A (en) 1996-06-06
US6005082A (en) 1999-12-21
WO1996015140A1 (en) 1996-05-23
SE503424C2 (sv) 1996-06-10
SE9403914D0 (sv) 1994-11-14
DE69528471T2 (de) 2003-07-10

Similar Documents

Publication Publication Date Title
DE69327582D1 (de) Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
SE9403914D0 (sv) Process B
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
UA41989C2 (uk) Фармацевтична композиція у вигляді гелю для лікування захворювань шкіри та спосіб лікування інфікованої шкіри
DE69430132D1 (de) Pernasale zusammensetzung und diese enthaltende pernasale zubereitung
DE69106493D1 (de) Sulfonische Stilbenderivate zur Behandlung von Viruserkrankungen.
IT1224867B (it) Dispositivo di supporto laterale, in particolare per l'arco mediano del piede
DK0661987T3 (da) Morphogeninduceret leverregeneration
US4678668A (en) Method of reducing soft tissue swelling and pain
ATE99932T1 (de) Verwendung von pyrrolicloncarbonsaeurealkylestern zur herstellung eines arzneimittels zur behandlung von ichtyosis.
FR2541115B1 (fr) Medicament renfermant un peptide en tant que principe actif pour le traitement des affections ulcereuses
DE60031016D1 (de) Verwendung von Antiseptika zur Herstellung von Arzneimitteln zur Prophylaxe und Behandlung von Entzündungen im Korperinneren des Menschen
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
DE69133077D1 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
DE69230491D1 (de) Transformierte zellen zur verhütung oder zur behandlung von virus-induzierten erkrankungen,besonders pathogenen retroviren
IE45054L (en) Veterinary composition
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
ES2129999T3 (es) Composicion gelificada estable con elevado contenido en electrolito.
ATE178208T1 (de) Capsaicin enthaltendes arzneimittel zur behandlung chronischer rhinopathie
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
KR970704442A (ko) 일시적인 병소 허혈에 의해 유발된 재관류 손상을 치료하기 위한 (S)-아데노실-L-메티오닌(SAMe) 및 그의 생리학상 적합한 염의 용도(Use of (S)-Adenosy-L-Methionine(SAMe) and lts Physiologically Compatible Salts for Treating Reperfusion Damage Triggered by Temporary Focal lschaemia)